Together, these findings confirm that CUDC-907 effectively targets both the PI3K/Akt signaling pathway and HDAC activity, resulting in enhanced growth inhibition and PR restoration in endometrial cancer cells. This evidence concerns the gene AKT1 and endometrial cancer.